Macrophage-derived granulomonopoietic enhancing activity (GM-EA) is a novel mediator that amplifies colony formation of myeloid progenitor cells (CFU-GM) in conjunction with colony-stimulating factors (CSFs). and is distinct from other hematopoietic synergizing factors such as interleukin (IL)-1, I L 4 , and IL-6. In the present study, we try to ascertain whether or not there is a GM-EA-specific responsive myeloid progenitor cell population. Human bone marrow cells deleted of adherent cells and T lymphocytes were separated by velocity sedimentation into three subpopulations with respective sedimentation rates (millimeters per hour) of 7.4 * 0.4.6.0 * 0.6. and 4.7 f 0.3. These subpopulations corresponded to the day 7 CFU-GM, day 14 CFU-GM, and the earlier myeloid progenitor cells, pre-CFU-
Low-density cells recovered at the interface were resuspended in a-minimal essential medium (a-MEM) containing 15% fetal calf serum (FCS) and then cultured in T,, culture flasks (Corning Glass Works, Corning, NY) at 37OC. After 90 minutes of incubation, the nonadherent cells were collected, washed, and further depleted of T lymphocytes by rosetting with aminoethylisothiuronium bromide (AET)-treated sheep red blood cells. 16 The low-density nonadherent and T-cell-depleted (LNAT-) bone marrow cells obtained usually contained less than 4% T cells as determined by immunofluorescence using monoclonal antibodies OKT3 and OKTl 1 (Ortho Diagnostic System, Raritan, NJ).
Conditioned medium from MDLMs (source of GM-EA) was prepared by culturing day 21 to 24 human macrophages in serum-free medium as described previou~ly.'~~'~ The GM-EA containing supernatants were collected after incubation at 37°C in 5% CO, for 3 days, and stored at -7OOC until use.
Purification of GM-EA was performed by anion-exchange chromatography and reverse-phase high performance liquid chromatography as described in detail e1~ewhere.I~ The purified GM-EA is a glycoprotein with an apparent molecular weight of 73 to 74 Kd. Its activity is about lo6 U/mg protein. One unit of activity is defined as the amount of GM-EA that can induce 20% enhancement of granulocyte-macrophage (GM) colony formation in cultures plated with 5 x lo4 low-density nonadherent bone marrow cells in the presence of 100 U of rGM-CSF.
Aliquots of purified GM-EA (200 pglO.1 mL) were emulsified in equal volumes of Freund's complete adjuvant and injected intramuscularly into three rabbits. The animals were boosted with two additional injections of GM-EA in Freund's incomplete adjuvant at the fourth and sixth weeks after the primary immunization. One week following the last injection, antisera were collected and partially purified by diethyl aminoethyl anion-exchange chromatography. One milligram of anti-GM-EA immunoglobulin G [IgG] could neutralize approximately 10, OOO U of GM-EA activity in the CFU-GM assay.
Reactivity of a n t 4 M -E A to various synergizing factors. The cytokine specificity of anti-GM-EA was determined using a solidphase enzyme-linked i " u n o a s s a y (EM). Briefly, 10 pg/well of each of the synergizing factors (GM-EA, rIGI, rIL-4, and rIL-6) was incubated with various dilutions of anti-GM-EA (1 mg/mL), and nonimmuned rabbit serum was included as the negative control. After 1 hour of incubation at 37oC. a second antibody of alkaline phosphataseconjugated goat anti-rabbit antiserum (Sigma Co, St Louis, MO) was added, and the results were then read with an enzyme-linked immunosorbent assay reader (Bio-Tek Instrument, Winooski, VT).
In addition, rabbit antisera against IL-1, IL-4, and IL-6 were allowed to react with GM-EA in parallel in the same manner.
Assay for IL-I. ILd. and IL-6. crude and purified GM-EA (2 to 4 U/mL) preparations were assayed for the presence of IL-1, IL-4, and IL-6 by commercially available assay kits (Genzyme) using a solid-phase E M as described by the manufacturer.
CFU-GM was assayed using a soft agar culture method as previously described."." Briefly, 5 x104 lowdensity and nonadherent human bone marrow cells were plated in a 1-mL layer of 0.3% agar in McCay's SA medium (GIBCO Lab, Grand Island. NY) containing 10% heat-inactivated FCS, essential and nonessential amino acids, vitamins, and pyruvate. Colony formation was induced by the addition of 100 U/dish of human rGM-CSF (or rG-CSF/rM-CSF/rIL-3) in the presence or absence of purified GM-EA (4 U/dish). Cultures were incubated at 37OC in a humidified atmosphere of 5% CO, in air. Colonies and clusters were scored after 7 and 14 days of incubation.
In some experiments, enhancement of G-M colony formation was induced by combinations of rGM-/rG-CSF (100 U/mL) with rIL-l/rlL-4/rIL-6 (100 U/mL), and the blocking effects of various anti-enhancing factor antisera were assesFed by preincubation of the enhancing factors (4 U/mL of GM-EA, 100 U/mL of rlL-l/rlL-4/ rIL-6) with their respective antibodies (5 NU/mL of anti-GM-EA, 100 NU/mL of anti-IGl/anti-lL-4/anti-IL-6) at 37OC for 90 minutes before addition to the CFU-GM assay cultures.
Morphologic observation of colonies and clusters were performed in situ as described pre~iously.'~ Assay for CFU-GEMM. CFU-GEMM was assessed by clonal culture as described by Lu et al. I7 Colony formation of pluripotent progenitor cells was induced by the addition of various concentrations (20 to 100 U/dish) of rIL-3 in the presence or absence of GM-EA (4 U/dish). One unit of erythropoietin was added to each dish on day 0. The cultures were incubated at 37OC in a humidified 5% CO, incubator for 14 days, and then scored for mixed colonies with an inverted microscope.
Velocity sedimentation. Velocity sedimentation was used to separate the different subpopulations of CRI-GM according to procedures described by Jacobsen et al.'* LNAT-human bone marrow cells (5 x lo7) were suspended in 40 mL of 0.2% bovine serum albumin ( S A ) in isotonic phosphatebuffered saline (PBS) and allowed to sediment at lg at 4% through a gradient of 0.4% to 2.0% BSA in PBS. After 3.5 hours, 35-mL fractions were collected, and the fractionated cells were then harvested, washed, and assayed for CFU-GM in the presence or absence of rGM-CSF (100 U/mL) and/or purified GM-EA (4 U/mL) at 5 x le cells/mL/plate.
The early developed myeloid progenitor cells, preXFU-GM, were obtained using suspension preculture according to the methods described by Jacobsen et all9 and Broxmeyer et al?' Briefly, LNAT-bone marrow cells were fractionated Assay for CFU-GM.
Suspension pieculture.
into different subpopulations by means of velocity sedimentation.
Cells corresponding to three peak fractions with respective sedimentation rates (millimeters per hour) of 7.46 .0, and 4.7 were collected, washed, and resuspended at 5 x 10' cells/mL in McCoy's 5A medium containing 10% FCS. One-milliliter aliquots of the cell suspension from each fraction were then cultured separately in the presence of rGM-CSF (100 U), GM-EA (4 U), or medium alone. After incubation at 37OC in 5% CO, for 7 days, the cells were harvested, washed, and resuspended in 1 mL of McCoy's 5A medium without counting, and 0.1-mL aliquots of the cell suspension were then assayed for CFU-GM using soft agar culture in the presence of rGM-CSF (100 U/dish).
RESULTS
Eflect of GM-EA on the colony formation of CFU-GM and CFU-GEMM. Colony formation of day 7 and day 14 CFU-GM was assayed in the presence or absence of different CSFs (rGM-CSF, rG-CSF, rM-CSF, and rIL-3). Results in Fig 1 show that GM-EA alone has no stimulatory effect on G-M colony formation, but can markedly promote the colony-stimulating effect of all the CSFs tested. The percent enhancement of colony formation by GM-EA was similar for day 7 CFU-GM and day 14 CFU-GM (Fig l) , with mean values of 70% to 80% and 55% to 70% for rGM-CSF and rG-CSF/rM-CSF/rIL-3, respectively. However, the profile of colony typing remained unchanged in the presence of GM-EA with each of the four CSFs (data not shown).
When the clonal growth of pluripotent progenitor cells was assayed in the presence of rIL-3 (multi-CSF) at 20 to 100 (% of CSF alonet) Low-density nonadherent human marrow cells were plated at 5 x 104/mL in a soft agar culture containing 100 U/dish of rGM-CSF/rG-CSF. Enhancement of colony formation was induced by the addition of various synergizing factors (4 U/mL of GM-EA or 100 U/mL ofrlL-l/rlL-4/rlL-6).
Results are expressed as the mean percent enhancement f SEM of three separate experiments. *Rabbit anti-GM-EA (5 NU/mL), anti-IL-1 (100 NU/mL), anti-lL-4
(100 NU/mL), or anti-IL-6 (100 NU/mL) was preincubated with various synergizing factors at 37°C for 90 minutes before addition to CFU-GM assay cultures. Antisera alone had no effect on CSF-induced colony formation.
?The numbers of G-M colonies induced by rGM-CSF and rG-CSF were 88 f 5 and 75 f 4 per 5 x 10' marrow cells, respectively.
U/mL, a dose-dependent response in mixed colony formation was noted after 14 days of incubation, and GM-EA when either used alone or in combination with IL-3 had no detectable stimulating or enhancing effect (data not shown). Efect of anti-enhancing factor antisera on colony enhancement. To rule out the possibility that GM-EA was related to other hematopoietic enhancing factors such as IL-1, IL-4, and IL-6, G-M colony enhancement was induced by rGM-/ rG-CSF in combination with various enhancing factors in the presence or absence of their specific antibodies. As shown in Table 1 , enhancement of G-M colony formation was seen when GM-EA, rlL-4, or rIL-6 was added to CFU-GM cultures in the presence of rGM-CSF/rG-CSF, whereas rIL-I had no synergism with either GM-CSF (Table 1) or G-CSF (data not shown). Anti-GM-EA antiserum could neutralize the enhancing activity of GM-EA but had no effect on IL-I, IL-4, and IL-6. In parallel, antisera specific for IL-I, IL-4, and IL-6 were unable to reduce the colonyenhancing activity of GM-EA (Table 1) . These results suggest that GM-EA is distinct immunologically and biologically from IL-1, IL-4, and IL-6.
Distinct properties of GM-EA compared with other enhancingfactors. An overview of the comparative characteristics of GM-EA with other hematopoietic enhancing factors (IL-I, IL-4, and IL-6) is summarized in Table 2 . GM-EA is distinct from these mediators based on the following criteria. First, GM-EA is constitutively secreted by the fully mature macrophages but not by the other cell types. Second, the molecular weight of GM-EA (73 to 74 Kd) as estimated by sodium dodecyl sulfate polyacrylamide gel electrophoresis is much higher than the other ILs. Third, based on EIA, specific anti-CM-EA antiserum has no detectable crossreactivity with any of the ILs, and GM-EA preparations have no detectable level of ILs 1, 4, and 6. Finally, the colony-enhancing profile of GM-EA is quite different from all of the ILs tested. Taken together, GM-EA is a novel enhancing factor that is specific for the myelopoietic progenitor cells.
Response of cell fractions from velocity sedimentation to GM-CSFIGM-EA. As indicated in Fig 2, three major subpopulations of myeloid progenitor cells were obtained from velocity sedimentation with respective peak sedimentation rates (SRs) of 7.4 f 0.4 mm/h (fraction A), 6 .0 f 0.6 mm/h (fraction B), and 4.7 f 0.3 mm/h (fraction C). Progenitor cells in fractions A and B were characterized by their clonogenic response to GM-CSF, while cells in fraction C were defined by their ability to generate small clusters (5 to 25 cells) in the presence of GM-EA alone at day 14 postincubation (Table 3 ). It is noteworthy that the efficiency of enhancement of GM-CSF by GM-EA is invariably higher using fractionated cells (greater than 8096) in comparison to assays with unfractionated cells because of the presence of large amounts of contaminating nonprogenitor cells in the crude preparations. Morphologic examination showed that the cells in fraction C consisted mostly of small lymphoid-like cells with diameters of 6 to 9 pm, and the GM-EA-induced clusters composed of mostly myelocytes and metamyelocytes/ Table 3 show that GM-EA alone had no stimulating effect on day 7 and day 14 CFU-GM, but it markedly promoted the colony formation of both myeloid LNAT-human bone marrow cells (5 x lo7) were allowed to sediment at 1 gat 4°C through a gradient of 0.4% to 2.0% BSA in PBS. After 3.5 hours, 35-mL fractions were collected and the cells were counted and assayed for colony formation in soft agar in the presence of rGM-CSF (100 U/dish) and/or purified GM-EA (4 U/dish). Results from three experiments are expressed as mean number of colony-forming units (CFU) per fraction.
Abbreviation: SR, sedimentation rate.
+The cell aggregates induced by GM-EA alone were small clusters (5 to tThe number in parentheses is colonies induced by rGMCSF plus 25 cells), and no colony formation could be observed.
GM-EA. Results from three separate experiments were expressed as mean CFU/fraction as percent of peak. Respective average numbers of CFU-GM in the peak fractions were: 11,182 on day 7 (fraction A). 6,643 on day 14 (fraction 6). and 2.040 for GM-EA responsive CFU (fraction C) on day 14.
progenitor subpopulations in the presence of GM-CSF. Furthermore, progenitor cells with low-velocity SR (less than 4.7 mm/h) failed to respond to GM-CSF alone, but could form colonies after treatment with GM-CSF plus GM-EA.
Eflect of GM-EA on suspension preculture of myeloid progenitor cell subpopulations. To further substantiate the differentiation status of the GM-EA target cells, we re-examined the response of enriched subpopulation of pre-CFU-GM to GM-EA by suspension preculture. Results in Fig 3 show that preculture of progenitor cells from fraction A (SR of 7.4 mm/h) invariably failed to generate myeloid colonies in subsequent CFU-GM assay, and only a few colonies could be induced from cells in fraction B (SR of 6.0 mm/h). However, the number of inducible colonies in fraction C (SR of 4.7 mm/h) was markedly higher than in the other two subpopulations. Furthermore, cells in fraction C treated with GM-EA generated fivefold more colonies than those treated with either GM-CSF or medium alone (Fig 3) . In addition, related hematopoietic regulators such as IL-1, IL-4, and IL-6 had not been detected in the supernatants of the day 7 suspension precultures (data not shown). These results suggest that the specific target cells of GM-EA are the "earlier" myeloid progenitor cells, pre-CFU-GM.
DISCUSSION
We have shown in a series of studies that GM-EA is a novel monokine produced by the well-developed macr~phages.l~-'~ This mediator is a myeloid lineage-specific growth factor that acted on the promotion of G-M colony formation induced by GM-CSA from various sources, but had no effect on the proliferation of erythroid or pluripotent progenitor cells.13 These findings were further substantiated in the present study using highly purified GM-EA and recombinant CSFs. Accordingly, GM-EA can enhance the colony formation of both day 7 and day 14 CFU-GM (Fig l) , but has no effect on CFU-GEMM. However, it remains uncertain whether GM-EA can act directly on certain population(s) of CFU-GM progenitor cells. Therefore, the aim of this study is to ascertain the effect of GM-EA on There is ample evidence to suggest that between the pluripotent stem cells and the CFU-GM there exists a subpopulation of progenitor cells, which is intermediate at its stage of mat~ration.'~.'~-~' This subpopulation has been referred to as CFUs in diffusion chambers (CFU-D)18*19,27-29 or as pre-CFU-GM derived from suspension preculture of bone marrow cells.19-20.2"30 Our observed velocity sedimentation profile of normal bone marrow cells is similar to that described by Jacobsen et all8 and shows three physically separable myeloid progenitor subpopulations corresponding to the day 7 CFU-GM, day 14 CFU-GM, and the "earlier" CFU-GM (Fig 2) . Among them, only the GM-CSF unresponsive "earlier" myeloid progenitor cells can be activated by GM-EA to proliferate in soft agar culture. It is unlikely that the action of GM-EA on the "earlier" CFU-GM is mediated indirectly through induction of other enhancing factors such as IL-1, IL-4, and IL-6, since before cell sedimentation we have removed the adherent cells and the T lymphocytes, which are the most probable candidates capable of exerting a feeder cell effect. Furthermore, the marrow stromal cells are relatively larger in size than the "earlier" myeloid progenitor cell (pre-CFU-GM), and most, if not all, of these contaminating cells would be expected to be removed after fractionation by velocity sedimentation. In addition, GM-EA has unique functional and antigenic properties that are distinct from ILs 1,4, and 6 (Tables 1 and 2) , and the ILs have no apparent effect on the ability of GM-EA to induce the proliferation of the pre-CFU-GM target cells (data not shown).
The GM-EA responsive progenitor cells are reminiscent of the CFU-D since they share the same velocity SR (4.7 to 5.2 mm/h). However, the two subpopulations differ in that CFU-D give rise to progeny cells of other types in addition to cells of granulopoietic lineage.28 This difference may arise from the fact that GM-EA is myeloid lineage-specific and the GM-EA responsive cells may be the counterpart of the neutrophilic CFU-D, which are regarded by some investigators as pre-CFU-GM since both of them can generate day 14 CFU-GM and express Ia-like (HLA-DR) antigen.24927.2s Results of our study with suspension preculture, which preferentially enriches pre-CFU-GM, also suggest that the specific target cells of GM-EA are indeed the pre-CFU-GM. Thus, only progenitor cells derived from the less mature subpopulation (SR of 4.7 mm/h) can generate a significant number of G-M colonies in soft agar culture while the more mature progenitors yield little or no colonies after suspension preculture (Fig 3) .
Coincidentally, Broxmeyer et aiZo have reported that adherent mononuclear bone marrow cells can release a pre-CFU-GM stimulating activity in suspension preculture, and such activity is most likely to be GM-EA. A similar phenomenon was noted by Bo1 and Williams3' that some enhancing activities in postendotoxin serum could potentiate the growth of CFU-GM. Taken together, GM-EA reactive cells may be a subpopulation of early committed myeloid progenitor cells referred to by others as pre-CFU-GM. However, the nature of their interaction remains to be determined and deserves further study.
In recent years, CSFs have been applied to clinical trials, and the preliminary results show that rG-CSF/rGM-CSF has promising effects on the treatment of some refractory diseases.32 Combination of chemotherapy with CSFs to prevent or reduce drug-induced myelosuppression is considered a hopeful approach to cancer therapy. 33 Our studies suggest that GM-EA may also have clinical application in conjugation with CSFs to improve the myelopoietic function of patients with marrow suppression. 
